Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
07/06/2024 | 12:59 | PR Newswire (US) | Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024 | NASDAQ:VTRS | Viatris Inc |
04/06/2024 | 12:59 | PR Newswire (US) | Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference | NASDAQ:VTRS | Viatris Inc |
03/06/2024 | 13:16 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:VTRS | Viatris Inc |
03/06/2024 | 12:59 | PR Newswire (US) | Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors | NASDAQ:VTRS | Viatris Inc |
31/05/2024 | 12:59 | PR Newswire (US) | Viatris to Participate in the Jeffries Global Healthcare Conference | NASDAQ:VTRS | Viatris Inc |
29/05/2024 | 00:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:VTRS | Viatris Inc |
28/05/2024 | 22:04 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:VTRS | Viatris Inc |
21/05/2024 | 12:59 | PR Newswire (US) | Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale | NASDAQ:VTRS | Viatris Inc |
09/05/2024 | 13:47 | IH Market News | U.S. Index Futures Dip, Bank of England Holds Interest Rates at 5.25% | NASDAQ:VTRS | Viatris Inc |
09/05/2024 | 12:59 | PR Newswire (US) | Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges | NASDAQ:VTRS | Viatris Inc |
02/05/2024 | 23:00 | PR Newswire (US) | Viatris to Participate in the BofA Securities 2024 Health Care Conference | NASDAQ:VTRS | Viatris Inc |
01/05/2024 | 12:59 | PR Newswire (US) | Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health | NASDAQ:VTRS | Viatris Inc |
16/04/2024 | 22:30 | PR Newswire (US) | Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 | NASDAQ:VTRS | Viatris Inc |
15/04/2024 | 14:00 | PR Newswire (US) | Viatris Appoints Corinne Le Goff as Chief Commercial Officer | NASDAQ:VTRS | Viatris Inc |
15/04/2024 | 12:59 | PR Newswire (Canada) | Viatris Announces Launch of First Bioequivalent Generic Version of Copaxone® 20 mg/mL Once-Daily in Canada | NASDAQ:VTRS | Viatris Inc |
15/04/2024 | 12:59 | PR Newswire (Canada) | Viatris annonce le lancement de la première version générique bioéquivalente du Copaxone [MD] 20 mg/mL au Canada | NASDAQ:VTRS | Viatris Inc |
01/04/2024 | 12:59 | PR Newswire (US) | Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States | NASDAQ:VTRS | Viatris Inc |
27/03/2024 | 11:59 | PR Newswire (US) | Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline | NASDAQ:VTRS | Viatris Inc |
06/03/2024 | 01:26 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:VTRS | Viatris Inc |
28/02/2024 | 12:30 | PR Newswire (US) | Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance | NASDAQ:VTRS | Viatris Inc |
28/02/2024 | 07:00 | PR Newswire (US) | Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration | NASDAQ:VTRS | Viatris Inc |
05/02/2024 | 12:59 | PR Newswire (US) | Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results | NASDAQ:VTRS | Viatris Inc |
30/01/2024 | 22:40 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:VTRS | Viatris Inc |
19/01/2024 | 12:56 | PR Newswire (US) | Viatris recognised as a Top Employer 2024 in the UK for the second consecutive year | NASDAQ:VTRS | Viatris Inc |
21/12/2023 | 22:05 | PR Newswire (US) | Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:VTRS | Viatris Inc |
15/12/2023 | 22:45 | PR Newswire (US) | Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer | NASDAQ:VTRS | Viatris Inc |
15/12/2023 | 22:05 | PR Newswire (US) | Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders | NASDAQ:VTRS | Viatris Inc |
24/11/2023 | 22:30 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:VTRS | Viatris Inc |
14/11/2023 | 14:00 | PR Newswire (US) | Viatris to Participate in the Jefferies London Healthcare Conference | NASDAQ:VTRS | Viatris Inc |
13/11/2023 | 14:00 | PR Newswire (US) | Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) | NASDAQ:VTRS | Viatris Inc |